UK markets closed

Pulmonx Corporation (LUNG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.27+0.16 (+1.76%)
At close: 04:00PM EDT
9.27 0.00 (0.00%)
After hours: 05:35PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.11
Open9.13
Bid9.23 x 100
Ask9.28 x 200
Day's range9.12 - 9.46
52-week range7.75 - 14.84
Volume583,119
Avg. volume495,349
Market cap357.242M
Beta (5Y monthly)0.60
PE ratio (TTM)N/A
EPS (TTM)-1.60
Earnings date30 Apr 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.83
  • GlobeNewswire

    Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today announced the inducement grant of equity awards to Steve Williamson, its newly-hired President and Chief Executive Officer, in accordance with Nasdaq Listing Rule 5635(c)(4). On March 15, 2024, Pulmonx granted Mr. Williamson (i) 205,286 time-based restricted stock units, which will vest as to 25% of such

  • GuruFocus.com

    Steven Cohen's Point72 Asset Management Bolsters Position in Pulmonx Corp

    Steven Cohen (Trades, Portfolio)'s Point72 Asset Management has recently made a notable addition to its investment portfolio by acquiring additional shares in Pulmonx Corp (NASDAQ:LUNG). The firm now holds a 5.00% stake in Pulmonx Corp, representing 0.04% of its investment portfolio. Steven A. Cohen, the Chairman and CEO of Point72 Asset Management, is a prominent figure in the investment world.

  • Business Wire

    Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial

    REDWOOD CITY, Calif., February 26, 2024--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), today announced the treatment of the first patient in the CONVERT II Pivotal Trial, a multicenter, international study evaluating the safety and effectiveness of the AeriSeal® System in limiting collateral ventilation in severe COPD/emphysema patients. Collateral ventilation is caused by openin